Year: 2025
Type: article
Study design: Observational Study
Abstract: This study identified novel autoantibodies in patients with seronegative myasthenia gravis (SNMG).Autoantibodies in SNMG sera were screened using a targeted binding assay (TBA). The target antigen was identified via immunoprecipitation and mass spectrometry, and validated by western blotting using a commercial antigen. A cell-based assay (CBA) employing HEK293 cells expressing the identified antigen was established to detect specific antibodies in 676 MG patients and 20 controls.Aldolase A (ALDOA) was identified as a novel autoantigen. Anti-ALDOA antibodies (ALDOA-Ab) demonstrated high diagnostic specificity in SNMG and were also detected in seropositive MG patients, with positivity rates of 4.89% in AChR-Ab' and 2.86% in MuSK-Ab' subgroups. ALDOA-Ab was predominantly of the IgG1 subclass. ALDOA-Ab may serve as a potential diagnostic biomarker for MG. Further studies are needed to investigate its pathogenic role.
Source: Frontiers in Neurology
Authors: Mengdi Zhang, Yingna Zhang, Peipei Liu, Qingye Gao, Qian Liu, Xinyue Zhou, Ruichen Liu, Xue Zhao, Jing Zhang, Jia Hu, Haiyan Dong, Jing Liu, Junhong Yang, Zhe Ruan, Ting Chang, Jie Lv, Feng Gao
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4415455335